Kpler: Asian crude oil imports are expected to recover to 22.18 million barrels per day in June.

金十2026/06/22 10:12

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Golden Ten Data reported on June 22 that Asia’s crude oil imports are expected to recover to pre-Iran conflict levels, but refined product supply remains constrained, and tight supply will be reflected in prices. According to data compiled by shipping intelligence firm Kpler, Asia is expected to import about 22.18 million barrels of crude oil per day in June, compared to 20.35 million barrels per day in May. The June import volume is still lower than the average of 26.76 million barrels per day in the three months before the United States and Israel launched an attack on Iran on February 28. However, this figure is significantly higher than April's eight-year low of 18.77 million barrels per day—April being the month most severely affected by Iran's effective closure of the Strait of Hormuz during the conflict. In addition, the situation where about 20% of global crude oil and refined products were transported through the Strait of Hormuz prior to the conflict may be restored, which will allow more oil to arrive in Asia in July.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)

路透社•2026/10/06 07:26